EPI01
Phase 1- Indications
- Sickle cell disease, Beta-thalassemia
Company intelligence / Profile preview
EpiDestiny
Cleveland, Ohio, United Statesepidestiny.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Phase 1
01
Overview
Currently conducting Phase 1 clinical trials for their lead program EPI01, an oral combination of decitabine and tetrahydrouridine for sickle cell disease. The therapy aims to increase fetal hemoglobin production to replace sickle cell hemoglobin.
- Therapeutic areas
- Hematology
- Modalities
- Small molecules (oral combination therapy)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Novo Nordisk A/S ($400 million licensing deal for EPI01)
Beyond the preview
Go deeper on EpiDestiny.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiDestiny.